|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2015
|
|
gptkbp:ATCCode
|
gptkb:L01XE29
|
|
gptkbp:brand
|
gptkb:Lenvima
|
|
gptkbp:CASNumber
|
417716-92-8
|
|
gptkbp:chemicalFormula
|
C21H19ClN4O4
|
|
gptkbp:combinationTherapy
|
gptkb:pembrolizumab
|
|
gptkbp:developedBy
|
gptkb:Eisai
|
|
gptkbp:eliminationHalfLife
|
28 hours
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits FGFR
inhibits KIT
inhibits PDGFRα
inhibits RET
inhibits VEGFR
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
426.85 g/mol
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
98-99%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:palmar-plantar_erythrodysesthesia
nausea
vomiting
diarrhea
fatigue
hypertension
weight loss
proteinuria
decreased appetite
stomatitis
|
|
gptkbp:usedFor
|
gptkb:cancer
gptkb:renal_cell_carcinoma
hepatocellular carcinoma
|
|
gptkbp:bfsParent
|
gptkb:VEGFR2
gptkb:protein_tyrosine_kinases
gptkb:Lenvima
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lenvatinib
|